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Purpose. To describe the distribution of ocular variables, risk factors, and disease severity in newly diagnosed ocular hypertension
(OH) or open-angle glaucoma (OAG). Methods. Eligible subjects underwent a complete history and examination. Adjusted odds
ratios (ORs) and 95% conﬁdence intervals (CIs) obtained from multiple logistic regression models were used to compare OAG
to OH and advanced to early/moderate OAG. Results. 405 subjects were enrolled: 292 (72.1%) with OAG and 113 (27.9%) with
OH. 51.7% had early, 27.1% moderate, and 20.9% advanced OAG. The OR for OAG versus OH was 8.19 (P<0.0001) for disc
notch, 5.36 (P<0.0001) for abnormal visual ﬁeld, 1.45 (P = 0.001) for worsening mean deviation, 1.91 (P<0.0001) for increased
cupping, 1.03 for increased age (P = 0.030), and 0.36 (P = 0.010) for smoking. Conclusions. Increased age was a risk for OAG,
and smoking decreased the risk of OAG compared to OH. Almost half of the OAG subjects had moderate/advanced disease at
diagnosis.
1.Introduction
Understanding disease risk factors is important for diagnosis
and treatment. Several glaucoma risk factors are known;
however, the literature is occasionally conﬂicting, suggesting
that risk factors may vary depending on glaucoma type and
stage [1]. Presently, risk factors with strongest evidence for
conversion of ocular hypertension (OH) to glaucoma, or
presence and progression of open-angle glaucoma (OAG),
include older age, thinner central corneal thickness (CCT),
greater cup-to-disc ratio (C/D ratio), and higher intraocular
pressure (IOP).
Other potential risk factors for the development or pro-
gression of OAG include gender [2–4], race [5], body mass
index(BMI)[6],myopia[7–11],bilateraldisease[12],family
history of glaucoma [7, 13–16], hypertension [7, 17–20], hy-
potension [21–23], smoking [24], thyroid disease [25, 26],
migraine [4, 27], Raynaud’s disease [28], concomitant medi-
cations (including corticosteroids, alpha-blockers, statins)
[29–31], asymmetric [32] and diurnal variation in IOP [33],2 Journal of Ophthalmology
sleep apnea [34], phakic status [35], optic disc size [36], disc
hemorrhage [37], pseudoexfoliation [8, 37], and pigment
dispersion [38].
The varying results of studies on glaucoma risk factors
require further research. We describe the presence and dis-
tribution of previously published glaucoma risk factors in
patients newly diagnosed with OH or OAG comparing these
two groups and analyze the distribution of risk factors in re-
lation to OAG disease severity.
2.MaterialsandMethods
This was a multicentre, prospective, noninterventional,
cross-sectional study registered with http://ClinicalTrials.gov
NCT00334750 conducted at 18 Canadian centers in accor-
dance with the Declaration of Helsinki and approved by the
ethics committee of each center.
Inclusion criteria included minimum age of 18 years,
diagnosed at or within 3 months of the study visit with
OH (at least one measurement of IOP ≥ 24mmHg and no
evidence of glaucomatous damage) or OAG (open angle on
gonioscopy and any two of the following: IOP ≥ 21mmHg,
glaucomatous optic neuropathy, and glaucomatous visual
ﬁeld defect), and willing and able to comply with study pro-
cedures, and provide written informed consent. Exclusion
criteria included subjects previously or currently receiving
ocular hypotensive therapy, a history of ocular surgery (ex-
cept cataract surgery), or ocular trauma.
The study consisted of one visit for each subject; how-
ever, some assessments were allowed within one month
of enrolment. The following information was collected on
standardized data collection sheets: demographics, medical
history, ocular family history, and complete ophthalmic ex-
amination including visual ﬁelds. Ocular data included re-
fraction, best corrected visual acuity, pupil responses, slit-
lamp biomicroscopy, and gonioscopy. Diurnal IOP (08:00,
10:00, 12:00, 14:00, and 16:00) was measured with a calibrat-
ed Goldmann applanation tonometer. CCT was measured
ultrasonically with 3 readings per eye averaged. Dilated fun-
dusexaminationwasperformedtoassessdiscsize,C/Dratio,
and presence of disc hemorrhage, peripapillary atrophy, and
nerve ﬁber layer defect (NFLD). Optic disc size was clas-
siﬁed based on comparing disc area with the target light of
a direct ophthalmoscope’s smallest aperture. If the disc ﬁts
the target it was classiﬁed “normal,” if smaller it was clas-
siﬁed “small,” and if larger, it was classiﬁed “large.” Visual
ﬁelds were performed using the Humphrey Field Analyzer
24-2 Swedish Interactive Thresholding Algorithm (SITA)
Fast (Carl Zeiss Meditec, Dublin, Calif, USA) and included
the Glaucoma Hemiﬁeld Test (GHT) analysis. Information
obtained included mean deviation (MD), pattern standard
deviation (PSD), and any abnormalities.
ClassiﬁcationasOHorOAGwasdeterminedbythestud-
y site. Severity of glaucoma was based on visual ﬁeld and op-
tic disc examination: advanced (C/D ratio ≥ 0.9 or MD <
−12.0dBorVFdefectwithin10◦ ofﬁxation),moderate(C/D
ratio 0.65–0.9 or MD −5.0 to −12.0dB, no VF defect with-
in 10◦ of ﬁxation), and early (C/D ratio ≤0.65 or MD >
−5.0dB, no VF defect within 10◦ of ﬁxation) [39].
2.1. Statistical Analysis. All analyses were based on data from
a single eye per subject. If both eyes qualiﬁed, the eye with
the worst disease was included; if equal, the right eye was
designated.
Descriptive statistics of demographic characteristics and
other potential risk factors for the two conditions (OAG and
OH)wereprovided.Tocomparediﬀerencesbetweenthetwo,
mean diﬀerence (and SD), 95% CI of the mean diﬀerence
and P-value were calculated for continuous variables, and
odds ratio (OR), 95% CI of odds ratio, and P-value for bi-
nary variables.
To assess which risk factors and/or ocular variables were
associated with OAG versus OH, adjusted ORs, along with
95% CIs, were obtained from multiple logistic regression
modelswithdiagnosis(OAGversusOH)astheresponsevar-
iable and risk factors and/or ocular variables as indepen-
dent variables. Correlation matrices checked for colinearity
between potential risk factors and/or ocular variables within
each of 3 classes of variables; highly correlated variables may
not have been jointly considered within a model. Potential
riskfactorswereselectedbasedonastepwiseprocedureusing
entryﬁxedat5%andstayﬁxedat10%.ORand95%CIswere
presented for the selected factors in the ﬁnal model (also
called reduced model).
Additionally, to assess which risk factors and/or ocular
variables were associated with severity of OAG, ordinal logis-
tic regression (proportional odds model) was performed,
with severity of disease (early, moderate, and advanced) as
a response variable and risk factors and/or ocular variables
as independent variables. Statistical analysis was performed
using SAS version 9.
3. Results
410 subjects were enrolled. Information regarding diagnosis
was available for 405 subjects who were analyzed. Overall,
404 (98.5%) subjects completed the study and 6 (1.5%)
subjects discontinued.
292 (72.1%) of 405 subjects were diagnosed with OAG
and 113 (27.9%) with OH. In OAG most had primary open-
angle glaucoma (POAG, 202/292, 69.2%). Other diagnoses
included normal tension glaucoma (65/292, 22.3%), pseu-
doexfoliation (16/292, 5.5%), and pigmentary glaucoma (9/
292, 3.1%). 151 (51.7%) of 292 subjects had early OAG at
diagnosis; a similar percent had moderate or advanced OAG:
79/292 (27.1%) and 61/292 (20.9%), respectively. Overall
60.5% of subjects (245/405) had symmetrical disease com-
pared with 39.5% (160/405) with asymmetrical disease. A
higherpercentageofsubjectswithOHhadsymmetricalﬁnd-
ings (73.5%) than subjects with OAG (55.5%).
Table 1 summarizes the demographic characteristics.
Subjects with newly diagnosed OAG were signiﬁcantly older
thanthosewithOH(63.0±13.0yearsforO A Gand56.5±12.6
for OH, P<0.0001). The distribution of male (145 OAG
versus 59 OH) and female (147 OAG versus 54 OH) subjects
was similar within the groups. The majority of subjects
were Caucasian (348/405; 85.9%) and the proportion of
Caucasian subjects was greater in OH, P = 0.013. MeanJournal of Ophthalmology 3
Table 1: Demographic characteristics.
Characteristic OAG
(n = 292)
OH
(n = 113)
P-valuea
Age groups, n (%) 0.001
18–44 years 22 (7.5) 15 (13.3)
45–64 years 137 (46.9) 70 (61.9)
≥65 years 133 (45.5) 28 (24.8)
Age, year, Mean ± SD 63.0 ±13.05 6 .5 ±12.6 <0.0001
(Range) (22–89) (21–91)
Male/female, n (%)
145
(49.7)/147
(50.3)
59 (52.2)/54
(47.8)
0.645
Race, n (%) 0.013
Caucasian 241 (82.5) 107 (94.7)
Black 18 (6.2) 1 (0.9)
Asian 26 (8.9) 3 (2.7)
Other 7 (2.4) 2 (1.8)
Weight, mean ± SD
(kg) 74.8 ± 15.6 80.9 ± 19.6 0.004
Height, mean ± SD
(cm) 168.0 ± 10.6 167.9 ± 9.1 0.937
BMI, Mean ± SD
(kg/m2) 26.5 ± 5.0 28.6 ± 6.0 0.001
Location, n (%) 0.015
Ontario 118 (40.4) 34 (30.1)
Quebec/atlantic 97 (33.2) 55 (48.7)
Western 77 (26.4) 24 (21.2)
Abbreviations: BMI: body mass index; n: number of subjects; OAG: open-
angle glaucoma; OH: ocular hypertension; SD: standard deviation.
aSigniﬁcance of diﬀerences between the OAG and OH groups was tested
using the chi-square test for categorical data and the t-test for continuous
data.
weight and BMI were both greater in OH, P = 0.004 and
0.001, respectively.
Table 2 summarizes the ocular examination results and
Table 3 the optic nerve assessment. The OAG subjects had
lower mean IOP, thinner CCT, and greater degree of myopia
than OH subjects. 6.2% of the OAG subjects had a relative
aﬀerent pupillary defect (RAPD) compared to none in OH
subjects, P = 0.005. For the optic nerve characteristics eval-
uated, more OAG subjects had abnormalities than OH. The
meanC/Dratiowas0.7±0.2inO A Gand0.4±0.2inOH,P<
0.0001. There were more large discs in OAG (13.7%) com-
pared to OH (6.2%), P = 0.035.
Table 4 summarizes the VF results. For each measure-
ment,themedianwasapproximatelydoubleorhigherforthe
OAG subjects; however, the 95% CIs were signiﬁcantly dif-
ferent for only MD, PSD, and false negative rate, and there
was a trend towards signiﬁcance for ﬁxation losses with P =
0.058.
The majority of subjects in both OAG and OH groups
had no family history of glaucoma (62.0%) or elevated IOP
(87.9%). Subjects with OH reported less frequent family his-
tory of blindness (3.5%) than subjects with OAG (11.0%),
P = 0.019. Overall, 45.1% of subjects with OH reported a
family history of glaucoma, elevated IOP, or blindness com-
pared with 42.1% of subjects with OAG.
Table 5 summarizes glaucoma risk factors by subjects’
medical histories; past or current histories were classiﬁed as
“yes.” The most frequently reported medical histories for the
OAGandOHgroups,respectively,werevasculardysfunction
(43.8%and32.7%),smoking(29.5%and46.9%),andhyper-
cholesterolemia (31.8% and 27.4%). There were no signif-
icant diﬀerences between the groups for all medical con-
ditions evaluated except vascular dysfunction and smoking
with P-values of 0.042 and 0.001, respectively.
The medication most frequently taken was statins, re-
ported by 83 (28.4%; 95% CI: 23.32–33.97) of 292 OAG sub-
jects and 23 (20.4%; 95% CI: 13.49–29.20) of 113 OH sub-
jects. There were no signiﬁcant diﬀerences between OAG
and OH subjects for any concomitant medication including
statins, corticosteroids, or alpha blockers.
Figure 1 shows which risk factors and ocular variables
were signiﬁcantly associated with diagnosis (OAG versus
OH) in the reduced model. The predicted odds ratio of OAG
for localized notch or thinning of neuroretinal rim was 8.19;
subjectswiththesefactorswere8.19timesmorelikelytohave
OAG than OH (95% CI: 2.93–22.88; P<0.0001). Subjects
who smoked had 0.36 times the odds of having OAG than
OH (95% CI: 0.17–0.78; P = 0.010). Additional signiﬁcant
risk factors were age (OR 1.03; 95% CI 1.00–1.06; P = 0.030)
per year increase, C/D ratio (OR 1.91; 95% CI: 1.54–2.37;
P<0.0001) per 0.1 unit increase, MD (OR 1.45; 95% CI
1.17–1.80; P = 0.001) per 1dB decrease, and abnormal VF
(OR 5.36; 95% CI: 2.12–13.56; P<0.0001).
Figure 2 shows which factors were associated with
advanced versus early or moderate OAG. Subjects with dif-
fuse or localized areas of pallor had over 5 times the odds as
subjects without pallor of having advanced OAG (95% CI:
1.27–21.10; P = 0.022) at diagnosis. Additional signiﬁcant
factors included worse MD (OR 1.25; 95% CI: 1.17–1.33;
P<0.0001),NFLD(OR2.60;95%CI:1.30–5.19,P = 0.007),
localizednotchorrimthinning(OR2.08;95%CI:1.12–3.86;
P = 0.021), presence of peripapillary atrophy (OR 2.66; 95%
CI: 1.51–4.69; P = 0.001), abnormal VF (OR 6.40; 95% CI:
3.15–12.99; P<0.0001), and presence of smoking (OR 1.89,
95% CI: 1.05–3.41; P = 0.034).
4. Discussion
Understanding glaucoma risk factors can aid diagnosis and
inﬂuence management decisions, including when to treat,
aggressiveness of treatment, and potentially developing new
treatment strategies. Our understanding of risk factors con-
tinues to evolve as the literature increases; however, publi-
cations have occasionally been conﬂicting thus underlining
the importance of continued studies. Some confusion may
relate to diﬀerentstudypopulations;forexample,riskfactors
for the conversion of OH to OAG may diﬀer from those for
incident OAG. Similarly, risk factors for progression of OAG
aswellasforstagesofglaucoma,andforgeographicorethnic
groups, may vary. Our study was designed to describe the
distribution of glaucoma risk factors in subjects with newly
diagnosed treatment-na¨ ıve OH and OAG. A comparison4 Journal of Ophthalmology
Table 2: Summary of ocular examination ﬁndings.
Variable
OAG OH Mean Diﬀerencea
P-valueb
N = 292 N = 113 (95% CI)
Mean Intraocular pressure ±SD, mmHgc 20.5 ±5.22 3 .4 ±3.3 −2.9 (−3.7, −2.0) <0.0001
Mean central corneal thickness ±SD, micronsd 554.2 ±38.2 583.4 ±34.6 −29.1 (−36.9, −21.4) <0.0001
Mean visual acuity ±SD, LogMAR 0.2 ±0.20 .1 ±0.2 0.1 (0.0, 0.1) <0.001
Mean spherical equivalence ± SD, diopterse −1.3 ±3.3 −0.6 ±2.5 −0.7 (−1.3, −0.0) 0.038
Abnormal anterior segment examination, n (%)f 19 (6.5) 10 (8.9) 0.7 (0.3, 1.6) 0.404
Presence of relative aﬀerent pupillary defect, n (%)f 18 (6.2) 0 (0.0) Inﬁnite (Inﬁnite) 0.005
Myopia, n (%)g 135 (46.2) 46 (40.7) 1.3 (0.8, 1.9) 0.316
Abbreviations: CI: conﬁdence interval; LogMAR: logarithm of the minimum angle of resolution; n: number of subjects; OAG: open-angle glaucoma; OH:
ocular hypertension; SD: standard deviation.
aMean diﬀerence calculated as OAG−OH.
bSigniﬁcance of diﬀerences between the OAG and OH groups was tested using the chi-square test for categorical data and the t-test for continuous data.
Fisher’s exact test was used for categorical data when the expected marginal size was <5.
cMissing data for 1 subject in the OH group.
dMissing data for 1 subject in the OAG group.
en = 266 in the OAG and n = 100 in the OH group.
fMissing data for 1 subject in both the OAG and OH groups.
gData concerning myopia were collected under medical history.
Table 3: Summary of optic nerve head examination ﬁndings.
Variable
OAG OH Mean diﬀerencea
P-valueb
N = 292 N = 113 (95% CI)
Mean C/D ratioc± SD 0.7 ±0.20 .4 ±0.2 0.3 (0.3, 0.3) <0.0001
Localized notch or thinning of the
neuroretinal rim, n (%)d 191 (65.4) 6 (5.4) 33.3 (14.2, 78.7) <0.0001
Presence of nerve ﬁber layer defect, n (%)d 55 (18.8) 0 (0.0) Inﬁnite (Inﬁnite) <0.0001
Presence of peripapillary atrophy, n (%)d 115 (39.4) 17 (15.2) 3.6 (2.1, 6.4) <0.0001
Presence of optic disc hemorrhage, n (%)d 15 (5.1) 1 (0.9) 6.0 (0.8, 46.1) 0.082
Diﬀuse or localized area of pallor, n (%)d 17 (5.8) 0 (0.0) Inﬁnite (Inﬁnite) 0.005
Large disc size, n (%) 40 (13.7) 7 (6.2) 2.4 (1.0, 5.5) 0.035
Abbreviations:C/D:cup-to-disc;CI:conﬁdenceinterval;n:numberofsubjects;OAG:open-angleglaucoma;OH:ocularhypertension;SD:standarddeviation.
aMean diﬀerences calculated as OAG-OH.
bSigniﬁcance of diﬀerences between the OAG and OH groups was tested using the chi-square test for categorical data and the t-test for continuous data.
Fisher’s exact test was used for categorical data when the expected marginal size was <5.
cC/D ratio: mean of horizontal and vertical C/D ratios; if 1 of 2 was missing, the nonmissing value was used as the average.
dMissing data for 1 subject in the OH group.
between OH and OAG groups provided OR for each factor.
Finally, risk factors were further analysed to determine an
association with disease severity.
We found that optic disc characteristics such as increased
C/D ratio, localized notching or thinning, NFLD, peripap-
illary atrophy, pallor, and disc hemorrhage were more com-
m o ni nO A Gt h a nO H .V Ff e a t u r e ss u c ha si n c r e a s e dM D ,
PSD, and GHT outside normal limits, defects within 10 de-
grees of ﬁxation, and false negative rate were all greater in
O A G .T h e s er e s u l t sa r ee x p e c t e da so p t i cd i s c ,a n dV Ff e a -
tures are used to diagnose disease and likely should not be
consideredasriskfactorsperse.However,sincemostofthese
ocular variables lack a clear distinction between deﬁnitive
glaucoma and normal (e.g., there is no cutoﬀ for C/D ratio
or MD to diagnose glaucoma), these were included in the
analysis.
A total of 11.6% (13/112) of the OH subjects’ VFs were
abnormalwith13%havingaGHToutsidenormallimitsand
24.1% with a defect within 10 degrees of ﬁxation. These ab-
normal VFs were not felt to be glaucomatous and may rep-
resentartifactorotherpathologysuchasage-relatedmacular
changes, and these subjects were not classiﬁed as having
OAG. Other ocular features more common in OAG were
worse acuity, presence of a RAPD, thinner CCT, and myopia.
In the ﬁnal multiple regression analysis, the only ocular vari-
ables that remained signiﬁcant included increased C/D ratio,
worse MD, abnormal VF, and localized notch or thinning.
ThinnerCCThaspreviouslybeenconsideredariskfactor
for both conversion of OH to OAG [2] and for the presence
of OAG [40–43]. In this study OAG had signiﬁcantly thinner
CCT compared to OH (554.2 ± 38.2µm versus 583.4 ±
34.6µm, resp.), P<0.0001; in the univariate analysis, how-
ever, CCT was not signiﬁcant in the regression model.Journal of Ophthalmology 5
Table 4: Summary of the Humphrey visual ﬁeld test ﬁndings.
Variable
OAG OH Mean diﬀerencea
P-valueb
N = 292 N = 113 (95% CI)
Mean ﬁxation losses ± SDc 9.3 ±13.27 .0 ±9.6 2.3 (−0.1, 4.6) 0.058
Mean false positive rate ± SD 3.6 ±5.94 .3 ±6.3 −0.71 (−2.1, 0.6) 0.299
Mean false negative rate ± SD 4.6 ±6.71 .9 ±4.1 2.7 (1.6, 3.8) <0.0001
Mean of mean deviation ± SD −4.6 ±5.7 −0.4 ±1.6 −4.1 (−4.8, −3.4) <0.0001
Mean pattern standard deviation ± SD 4.4 ±3.61 .7 ±0.8 2.7 (2.3, 3.1) <0.0001
Visual ﬁeld unreliable, n (%) 43 (14.7) 16 (14.2) 1.0 (0.6, 1.9) 0.885
Presence of artifacts, n (%)c 10 (3.4) 5 (4.5) 0.8 (0.3, 2.3) 0.625
Abnormal visual ﬁeld overall, n (%)c 181 (62.2) 13 (11.6) 12.5 (6.7, 23.4) <0.0001
Within 10◦ of ﬁxation, n (%)d 134 (45.9) 27 (24.1) 2.7 (1.6, 4.4) <0.0001
Glaucoma hemiﬁeld test outside
normal limits, n (%)e 166 (59.1) 14 (13.0) 9.7 (5.3, 17.8) <0.0001
Abbreviations: CI: conﬁdence interval; n: number of subjects; OAG: open-angle glaucoma; OH: ocular hypertension; SD: standard deviation.
aMean diﬀerence calculated as OAG −OH.
bSigniﬁcance of diﬀerences between the OAG and OH groups was tested using the chi-square test for categorical data and the t-test for continuous data.
Fisher’s exact test was used for categorical data when the expected marginal size was <5.
cMissing data for 1 subject in both the OAG and OH groups.
dMissing data for 1 subject in the OH group.
en: 281 in the OAG and n: 108 in the OH group.
Table 5: Summary of medical history, n (%).
Medical history
(past or current)
OAG OH Odds ratio P-valuea
N = 292 N = 113 (95% CI)
Vascular dysfunction 128 (43.8) 37 (32.7) 1.6 (1.0, 2.5) 0.042
Hypercholestero- lemia 93 (31.8) 31 (27.4) 1.2 (0.8, 2.0) 0.387
Smoking 86 (29.5) 53 (46.9) 0.5 (0.3, 0.7) 0.001
Migraine 37 (12.7) 16 (14.2) 0.9 (0.5, 1.7) 0.690
Thyroid disease 34 (11.6) 15 (13.3) 0.9 (0.4, 1.7) 0.652
Diabetes mellitus 32 (11.0) 17 (15.0) 0.7 (0.4, 1.3) 0.258
Pseudoexfoliation
syndrome
19 (6.5) 3 (2.7) 2.6 (0.7, 8.8) 0.148
Raynaud’s disease 15 (5.1) 5 (4.4) 1.2 (0.4, 3.3) 0.767
Pigment dispersion
syndrome
12 (4.1) 6 (5.3) 0.8 (0.3, 2.1) 0.599
Sleep apnea 9 (3.1) 7 (6.2) 0.5 (0.2, 1.3) 0.149
Abbreviations: CI = conﬁdence interval; n = number of subjects; OAG = open-angle glaucoma; OH = ocular hypertension.
aSigniﬁcance of diﬀerences between the OAG and OH groups was tested using the chi-square test; Fisher’s exact test was used when the expected marginal size
was <5.
IOP has consistently been recognized as a glaucoma risk
factorincludingboththemeanlevel[2,12,14,21,30,44–47]
and degree of ﬂuctuation [33, 47]. In our study, mean IOP
was higher in OH as compared to OAG, 23.4 ± 3.3mmHg
versus 20.5 ± 5.2mmHg, respectively (P<0.0001). This dif-
ference is explained both by the deﬁnition of OH (at least
one IOP measurement of ≥24mmHg) and the frequency of
normal-tension glaucoma (65/292, 22.3%) in OAG.
Evaluation of nonocular variables found the following
signiﬁcant diﬀerences between the groups: younger age (56.5
± 12.6 versus 63.0 ±13.0, P<0.0001), greater proportion of
Caucasian subjects (94.7% versus 82.5%. P = 0.013), higher
weight (80.9±19.6v e r s u s7 4 .8±15.6kg,P = 0.004), greater
BMI (28.6 ± 6.0v e r s u s2 6 .5 ± 5.0kg/m 2, P = 0.001), and
higher frequency of smoking history (46.9% versus 29.5%,
P = 0.001) in the OH versus OAG group, respectively. Of
these,onlyageandsmokingweresigniﬁcantintheﬁnalmul-
tiple regression analysis.
Age is a recognized risk factor for glaucoma [48–51]. The
resultsforsmokingarecontroversial.Wefoundthatahistory
of smoking (past or current) was protective with an odds
ratio of 0.36 (P = 0.010) for OAG versus OH. Cigarette
smoking is linked to many diseases including cataracts [52]
andmaculardegeneration[53].Epidemiologicalstudieshave
also found a negative correlation between smoking and the
development of neurodegenerative disorders such as Parkin-
son’s, and in some studies, Alzheimer’s disease [54]. One
large prevalence survey found no association between smok-
ing and POAG [55]. Finally, for concomitant medications
it has previously been suggested that statin use may be6 Journal of Ophthalmology
Age
Cup-to-disc ratio
Mean deviation
Visual ﬁeld overall
Localized notching or thinning
Location
Smoking
Adjusted odds ratio and 95% conﬁdence interval
Favors OH (1) Favors OAG
1.03 1–1.06 0.03
1.91 1.54–2.37 <0.0001
1.45 1.17–1.8 0.001
5.36 2.12–13.56 <0.0001
8.19 2.93–22.88 <0.0001
0.27 0.11–0.63 0.003
0.36 0.17–0.78 0.01
0.01 0.1 1 10 100
Risk factor OR 95% Cl P-value
Figure 1: Association of primary diagnosis versus risk factors (reduced model). (i) Primary diagnosis: OAG versus OH. (ii) Age, cup-to-
disc ratio, and mean deviation are continuous variables, and the others are categorical. Age was estimated in every one-year increment,
cup-to-disc ratio in every 0.1-unit increment, and mean deviation in every 1dB unit of worsening. Categorical variables were estimated
as follows: visual ﬁeld overall (abnormal versus normal, localized notching/thinning (Yes versus No), location (Quebec/Atlantic versus
Ontario), smoking (Yes versus No). (iii) Odds ratio, 95% conﬁdence interval. (1) OR = 1 implies a speciﬁc risk factor is equally likely in
both OAG and OH groups, OR >1 implies more likely in OAG, and OR < 1 implies more likely in OH.
Risk factor
Mean deviation
Nerve ﬁber layer defect
Localized notching or thinning
Disc pallor
Peripapillary atrophy
Visual ﬁeld overall
Smoking
Adjusted odds ratio and 95% conﬁdence interval
Favors early/moderate (1) Favors Advanced
OR 95% Cl P-value
1.25 1.17–1.33 <0.0001
2.6 1.3–5.19 0.007
2.08 1.12–3.86 0.021
5.17 1.27–21.1 0.022
2.66 1.51–4.69 0.001
6.4 3.15–12.99 <0.0001
1.89 1.05–3.41 0.034
0.01 0.1 1 10 100
Figure 2: Association of severity of OAG versus risk factors (reduced model). (i) severity of OAG. Advanced disease versus early or moderate
disease.(ii)Meandeviation (MD)isacontinuousvariable, andtheothersarecategorical. MDwasestimatedinevery1dBunitofworsening.
Categorical variables were estimated as follows: nerve ﬁber layer defect, localized notching/thinning, disc pallor, peripapillary atrophy,
smoking (Yes versus No) and visual ﬁeld overall (abnormal versus normal). (1) OR = 1 implies a speciﬁc risk factor is equally likely in
both severity levels, OR > 1 implies more likely in advanced, and OR < 1 implies more likely in early/moderate.Journal of Ophthalmology 7
protective for OAG [31]. Statin use in our study was not
signiﬁcant in the univariate or ﬁnal multiple regression anal-
ysis.
Study location was signiﬁcant in both the univariate and
ﬁnalmultipleregressionmodelwhencomparingQuebec/At-
lantic region to Ontario but was not signiﬁcant for com-
parisons including the Western region. The diagnosis of OH
occurred more frequently in Quebec/Atlantic region than
Ontario (48.7% versus 30.1%, resp.), and the diagnosis of
OAG was more frequent in Ontario than Quebec/Atlantic
region (40.4% versus 33.2%, resp.), P = 0.015. In the ﬁnal
multiple regression model, the OR of OAG versus OH was
0.27 (95% CI 0.11–0.63) for Quebec/Atlantic region versus
Ontario. The signiﬁcance of this ﬁnding is unclear, and fur-
ther study of this is warranted.
We evaluated OAG by severity of disease at diagnosis
using the deﬁnition of Damji et al. [39]. Almost half the sub-
jects with OAG presented with moderate or advanced disease
at diagnosis. Evaluation of various risk factors using logistic
regression analysis found the presence of a NFLD, optic disc
pallor,peripapillaryatrophy,localizednotchorrimthinning,
and smoking to be signiﬁcant in addition to variables
associated with the deﬁnition of severity (MD and abnormal
VF). It is interesting that smoking was a risk factor for OH
when compared to OAG; however, within the OAG group, a
history of smoking was a signiﬁcant risk factor for advanced
disease. This seemingly conﬂicting result deserves further
study. Possibly our deﬁnition of smoking, with “yes” deﬁned
as a previous or current history of smoking, is obscuring the
results. Perhaps a deﬁnition of smoking including duration
and number of cigarettes per day might provide a diﬀerent
conclusion.
There are limitations to our study. Firstly, many of the
ocular variables studied are used in the deﬁnition of OAG
and likely should not be considered risk factors perse; how-
ever, these are often reported, and given the lack of a clear
distinction between disease and no disease for most of these
variables, we included them in the analysis. Secondly, self-
reported risk factors including family and medical history
may be unreliable. Finally, there may be selection bias as this
study relied on the diagnosis of OAG and OH from the study
site. To minimize this optic disc, visual ﬁeld reading centers
were responsible for independently verifying results.
5. Conclusions
In summary, we evaluated the distribution of previously
published risk factors for glaucoma in subjects with newly
diagnosed OH or OAG. In addition, within OAG, we eval-
uated risk factors in terms of disease severity. Logistic regres-
sion analysis determined several factors to be signiﬁcantly
associated with OH or OAG and severity of OAG. An in-
teresting result was a history of smoking, which seemed to
b ep r o t e c t i v ef o rO A Gv e r s u sO H ;h o w e v e r ,w i t h i nO A G ,i t
was a signiﬁcant risk factor for advanced disease at presen-
tation. In addition, subjects with advanced versus early or
moderate OAG, the presence of a NFLD, optic disc pallor,
peripapillary atrophy, and localized notch or rim thinning
were all associated with advanced disease (OR 2.60, 5.17,
2.66, 2.08, resp.). Finally, we found that nearly 50% of sub-
jects with OAG presented with moderate or advanced dis-
ease at initial diagnosis. This ﬁnding alone supports the im-
portance of further studies regarding risk factors to assist in
earlier diagnosis of glaucoma.
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